Ono Pharma partners with Mediar Therapeutics to discover antibody therapies for fibro-inflammatory diseases
- nuaxia
- 7 ago
- 2 min de lectura
The research collaboration combines Mediar’s fibrosis biology and antibody discovery capabilities with Ono’s drug development expertise to identify new treatments targeting fibro-inflammatory disease mechanisms.
Ono Pharmaceutical has entered a drug discovery partnership with Mediar Therapeutics to identify and develop novel antibody therapeutics against an undisclosed target involved in fibro-inflammatory diseases, with Mediar receiving an upfront payment and research funding alongside potential future milestone payments and royalties.
The collaboration expands Ono’s access to specialist fibrosis biology while providing Mediar with funding and a potential route to advance newly discovered antibodies into global clinical development and commercialisation.
Field | Content |
Alert Type | Deal |
Companies | Ono Pharmaceutical; Mediar Therapeutics |
Deal Type | Drug discovery and research collaboration |
Asset or Company | Novel antibody therapeutics against an undisclosed target associated with fibro-inflammatory diseases |
Therapy Area(s) | Fibrosis; Inflammatory diseases |
Technology or Modality | Antibody therapeutics |
Deal Value | Financial terms were not fully disclosed. Mediar will receive an upfront payment and research funding and is eligible for research, development, regulatory and commercial milestone payments, plus tiered royalties on future global net sales. |
Development Stage | Discovery |
Geography | Global |
What Happened | On 6 August 2026, Ono Pharmaceutical and Mediar Therapeutics announced a drug discovery partnership to create novel antibody therapeutics targeting an undisclosed molecule involved in fibro-inflammatory diseases. Mediar will use its expertise in fibrosis biology and antibody discovery to conduct research and identify therapeutic candidates. Ono will have the right to obtain an exclusive worldwide licence to develop and commercialise resulting antibodies, subject to the terms of the agreement. |
Why It Matters | Fibro-inflammatory diseases involve persistent inflammation and pathological fibrosis that can progressively impair organ function, creating a need for therapies that intervene in the biological mechanisms driving fibrosis. The collaboration gives Ono access to Mediar’s specialised fibrosis research capabilities and potential new antibody candidates, while the early discovery stage means their therapeutic potential remains to be established. |
Supporting Context | Mediar Therapeutics focuses on developing therapies that target myofibroblasts, cells involved in the development and progression of fibrosis. The company is building a pipeline of antibody-based programmes intended to intervene in fibrosis across multiple organ systems. |
Strategic Rationale | Ono gains access to Mediar’s expertise in fibrosis biology and antibody discovery without acquiring the company or an existing clinical-stage asset. Mediar receives upfront and research funding while retaining the opportunity to earn milestones and royalties if Ono exercises its licensing rights and resulting programmes progress successfully. |
Potential Impact | If the collaboration identifies viable therapeutic candidates, it could add new antibody programmes to Ono’s pipeline and extend Mediar’s fibrosis research into additional fibro-inflammatory diseases. Any clinical or commercial impact will depend on successful discovery, preclinical development, licensing and subsequent clinical trials. |
Key Takeaway | The partnership gives Ono access to Mediar’s specialised fibrosis discovery capabilities while creating a route for new antibody programmes to progress towards global development. |
What to Watch | Identification of lead antibody candidates, Ono’s exercise of its exclusive licensing rights and any subsequent preclinical or clinical development programmes arising from the collaboration. |
Primary Source | |
Relevant Date | 6 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios